Home Japanese values Takeda Pharmaceutical Announces Strategic Leadership Changes

Takeda Pharmaceutical Announces Strategic Leadership Changes

0

OSAKA, Japan and CAMBRIDGE, Massachusetts, February 3, 2022 – Takeda (TSE:4502/NYSE:TAK) today announced changes to its leadership team to continue to drive long-term growth in a highly competitive and dynamic global marketplace. The executive changes, unless otherwise noted, will be effective at the start of Takeda’s 2022 fiscal year (April 1, 2022) and these executives will report to President and CEO Christophe Weber:

  • Gabriel Ricci, who previously served as Head of IT for the Plasma-Derived Therapies (PDT) business unit has been appointed Chief Data and Technology Officer of Takeda, effective February 1, 2022. In this role, Gabriele will lead the critical transformation of the company’s Data, Digital and Technology division. Elevating and evolving the company’s existing IT function demonstrates the company’s commitment to creating an industry-leading approach to data and technology to ultimately help better deliver treatments that transform the lives of patients and society.
  • Ramona Sequeira, who currently serves as president of the US business unit and global portfolio marketing, has been named president of the global portfolio division. This newly created division at Takeda will bring together three global teams and three regional businesses to ensure the company can successfully bring new and existing global products to patients. Specifically, Ramona will oversee Global Medical, Global Product Launch Strategy, Vaccines Business Unit as well as three regional business units including Europe & Canada, Growing & Emerging Markets and China Business Unit.
  • Julie Kim, who is currently President of the PDT Business Unit, has been appointed President of the US Business Unit and US Country Manager. In this role, Julie will focus on the continued growth of Takeda’s business in the United States, a key market for the company’s success.
  • Gilles Platford, who is currently president of the Europe and Canada business unit, has been named president of the PDT business unit, which will remain one of Takeda’s key revenue growth drivers in the coming years.

“My leadership team has been instrumental in transforming Takeda into a global, values-driven biopharmaceutical company that delivers transformational medicine to patients around the world. Our strategy is working and we continue to grow — with a competitive scale, a global market and a diverse pipeline with approximately 40 new molecular entities in clinical development,” said Christophe Weber, President and CEO of Takeda. “We look to the future, with clear goals in mind, including the opportunity to strengthen our global launch capabilities and harness data and digital to revolutionize the patient experience. This is the team that will help us take it to the next level and ensure we continue to grow and evolve.”

In addition, Takeda will expand the roles of other members of the management team, including Lauren Duprey, Director of Human Resources, focus more on employee well-being; Takako Ohyabu, Global Corporate Affairs and Sustainability Director, accelerate the achievement of our goal-oriented sustainability agenda; and Mwana Lugogo, Global Ethics and Compliance, to include data privacy. Takeda will also continue to focus and commit to its oncology business unit and Japan business unit, as well as its other critical functional areas such as research and development, finance, business development, human resources. , Quality, Ethics & Compliance, Legal, Global General Affairs, Corporate Strategy and Manufacturing with executive leadership of these areas continue to report to Mr. Weber.

About Takeda

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discovering and delivering life-transforming treatments, guided by our commitment to patients, our people and the planet. . Takeda focuses its R&D efforts on four therapeutic areas: oncology, rare genetics and hematology, neurosciences and gastroenterology (GI). We also make targeted R&D investments in plasma-derived therapies and vaccines. We are focused on developing highly innovative medicines that help make a difference in people’s lives by pushing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust pipeline and diversified in terms of modalities. Our employees are committed to improving the quality of life for patients and working with our healthcare partners in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

Media Contacts

Japanese media

Ryoko Matsumoto
[email protected]
+81 (0) 3-3278-3414

American and international media

Megan Ostrow
[email protected]
+1 772-559-4924

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) relating to this release. This press release (including any oral presentation and any Q&As relating thereto) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer for purchase, otherwise acquire, subscribe, exchange, sell or otherwise dispose of securities or solicit a vote or approval in any jurisdiction. No shares or other securities are offered to the public by means of this press release. No offer of securities will be made in the United States except pursuant to registration under the US Securities Act of 1933, as amended, or an exemption therefrom. This press release is given (together with any other information which may be provided to the recipient) on the condition that it is to be used by the recipient for informational purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly hold investments are separate entities. In this press release, “Takeda” is sometimes used for convenience when referring to Takeda and its affiliates generally. Similarly, the words “we”, “us” and “our” are also used to refer to affiliates in general or the people who work for them. These expressions are also used when it is not useful to identify the particular company or companies.

Forward-looking statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts , goals and plans for Takeda. Without limitation, forward-looking statements often include words such as “objectives”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensure”, “will”, “may”, “should”, “would”, “could”, “anticipate”, “estimate”, “plan” or similar expressions or their negative form. These forward-looking statements are based on assumptions about many important factors, including the following, that could cause actual results to differ materially from those expressed or implied by the forward-looking statements: economic circumstances surrounding the global business of Takeda, including general economic conditions in Japan and the United States; competitive pressures and developments; changes in applicable laws and regulations, including global healthcare reforms; challenges inherent in the development of new products, including the uncertainty of clinical success and the decisions of regulatory authorities and the timing thereof; the uncertainty of the commercial success of new and existing products; manufacturing difficulties or delays; interest rate and currency exchange rate fluctuations; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, such as the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in the countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to dispose of assets that are not essential to Takeda’s operations and the timing of such disposals; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the United States Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rules. Past performance is not an indicator of future results and Takeda’s results or statements in this press release may not be indicative and do not constitute an estimate, forecast, guarantee or projection of Takeda’s future results.